SEATTLE, WA -- (MARKET WIRE) -- January 18, 2007 -- Targeted Genetics Corporation (NASDAQ: TGEN) today announced publication of positive results from a preclinical study of intramuscular administration of a pseudotyped AAV2/1-TNFR:Fc vector, in the February issue of Molecular Therapy. The study, led by Dr. Haim Burstein, Senior Director, Product Discovery for Targeted Genetics, establishes a proof of concept for administration of AAV-TNFR:Fc vector to the muscle for the purpose of achieving long-term, sustained and therapeutically relevant levels of TNFR:Fc protein to treat chronic systemic inflammatory joint disease. The article is titled “Long-term Suppression of Experimental Arthritis Following Intramuscular Administration of a Pseudotyped AAV2/1-TNFR:Fc Vector.” Molecular Therapy is the official publication of the American Society of Gene Therapy.
